| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d16c73833a9ec380ce18fa4a3b5eefb2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4826
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-04 |
| filingDate |
2017-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f5cb402d0c313e4d3a8ac83fb3a981e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e587941a07227f33eb6cad4a8b0605de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea9941fbf83b9ba3a8e60c63349e44b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e2c82eb7bfc048bb49fd43b27cbffac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_083c2ec00a12edcb74dd3c0b8cc4e929 |
| publicationDate |
2019-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10350239-B2 |
| titleOfInvention |
Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent |
| abstract |
The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumor cell to enhance cell-to-cell adhesion of tumor cells, effect proteolysis of tumor cells, or induce tumor cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumor cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022261440-A1 |
| priorityDate |
2009-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |